Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate the efficacy and safety of DW4902, a novel oral gonadotropin-releasing hormone (GnRH) antagonist, in premenopausal women with uterine fibroids and heavy menstrual bleeding (HMB). DESIGN: Multicenter, randomized, double-blind, placebo-controlled Phase II trial. SETTING: Twelve tertiary hospitals in Korea. POPULATION: Premenopausal women with uterine fibroids and heavy menstrual bleeding, defined as a screening pictorial blood assessment chart score (PBAC) ≥ 120. METHODS: Seventy-one women with uterine fibroids, HMB (screening PBAC ≥ 120) and other predefined criteria were randomized to placebo or DW4902 160, 240 or 320 mg once daily. MAIN OUTCOME MEASURES: The primary endpoint was the proportion achieving PBAC < 10 during Weeks 6-12. Secondary endpoints included amenorrhea, haemoglobin change, fibroid and uterine volumes, pain scores, bone mineral density and safety. RESULTS: During Weeks 6-12, PBAC < 10 was achieved by 73.33%-100.00% of participants receiving DW4902 160, 240 and 320 mg (p < 0.0001). Amenorrhea rates were likewise significantly higher in the DW4902 groups (≥ 73.33%), with bleeding suppression evident from Weeks 2 to 6. Haemoglobin levels increased significantly in the 160 and 240 mg groups. Fibroid and uterine volumes and fibroid-related pain were significantly reduced across all DW4902 dose groups. Hormone levels recovered after treatment discontinuation, and lumbar spine bone mineral density showed modest, reversible changes. Adverse events were mostly mild and comparable between groups, with no serious drug-related events. CONCLUSIONS: DW4902 demonstrated a robust efficacy in reducing menstrual bleeding and improving fibroid-related outcomes with an acceptable short-term safety and bone density profile.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: